Celgene (NASDAQ:CELG) Sets New 12-Month High at $99.00

Celgene Co. (NASDAQ:CELG)’s share price hit a new 52-week high on Thursday . The stock traded as high as $99.00 and last traded at $98.97, with a volume of 167040 shares traded. The stock had previously closed at $98.41.

Several brokerages recently weighed in on CELG. BidaskClub lowered Celgene from a “buy” rating to a “hold” rating in a research report on Saturday, September 7th. ValuEngine lowered Celgene from a “sell” rating to a “strong sell” rating in a research report on Thursday, August 1st. Mizuho lowered Celgene from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $103.00 to $100.00 in a research report on Monday, August 19th. Zacks Investment Research upgraded Celgene from a “sell” rating to a “hold” rating and set a $94.00 price objective for the company in a research report on Tuesday, July 23rd. Finally, Cowen reiterated a “hold” rating and issued a $102.00 price objective on shares of Celgene in a research report on Tuesday, July 30th. One investment analyst has rated the stock with a sell rating, eighteen have issued a hold rating and three have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $94.60.

The firm has a 50-day moving average price of $94.93 and a 200 day moving average price of $93.38. The firm has a market capitalization of $68.80 billion, a PE ratio of 12.96, a price-to-earnings-growth ratio of 0.45 and a beta of 1.41. The company has a quick ratio of 3.32, a current ratio of 3.44 and a debt-to-equity ratio of 1.97.



Celgene (NASDAQ:CELG) last released its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $2.61 EPS for the quarter, topping the consensus estimate of $2.44 by $0.17. Celgene had a return on equity of 89.93% and a net margin of 32.24%. The business had revenue of $4.40 billion during the quarter, compared to analyst estimates of $4.22 billion. During the same period last year, the business posted $2.16 earnings per share. The company’s quarterly revenue was up 15.4% on a year-over-year basis. Equities research analysts expect that Celgene Co. will post 9.96 earnings per share for the current year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Berman Capital Advisors LLC increased its position in shares of Celgene by 11.3% during the second quarter. Berman Capital Advisors LLC now owns 1,096 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 111 shares in the last quarter. Bbva USA Bancshares Inc. grew its holdings in shares of Celgene by 0.8% during the second quarter. Bbva USA Bancshares Inc. now owns 13,271 shares of the biopharmaceutical company’s stock worth $1,227,000 after buying an additional 111 shares during the last quarter. Plancorp LLC grew its holdings in shares of Celgene by 5.1% during the second quarter. Plancorp LLC now owns 2,336 shares of the biopharmaceutical company’s stock worth $216,000 after buying an additional 113 shares during the last quarter. Global Retirement Partners LLC grew its holdings in shares of Celgene by 10.0% during the first quarter. Global Retirement Partners LLC now owns 1,269 shares of the biopharmaceutical company’s stock worth $120,000 after buying an additional 115 shares during the last quarter. Finally, MBM Wealth Consultants LLC grew its holdings in shares of Celgene by 2.8% during the second quarter. MBM Wealth Consultants LLC now owns 4,264 shares of the biopharmaceutical company’s stock worth $397,000 after buying an additional 116 shares during the last quarter. Institutional investors and hedge funds own 72.51% of the company’s stock.

About Celgene (NASDAQ:CELG)

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Further Reading: Stock Symbols Definition, Examples, Lookup

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.